Nervous Disorder TRIZ Cases

Genotyping CYP2C19, CYP3A4, and ABCB1 variants reduces adverse events by tailoring cannabidiol administration to individual metabolic profiles.

Segmented VHH structures detect toxic Tau oligomers, enabling early Alzheimer's diagnosis.

A gelled oil-in-water emulsion formulation creates a solid-like barrier that resists mechanical crushing and solvent extraction.

Protease-resistant dynamin mutants stabilize podocyte ultrafiltration barriers, preventing cathepsin L degradation and proteinuria.

A microRNA biomarker panel detects neurodegenerative disorders through specific molecular signatures in cerebrospinal fluid samples.

Aluminium oxyhydroxide adjuvant triggers endogenous antibody production to clear amyloid-beta deposits.

A processed wasabi product containing ω-methylsulfinylalkyl isothiocyanate treats chronic fatigue syndrome symptoms without psychotropic drug side effects.

Oxalate, 4-aminosalicylate, and cyclamate salts resolve poor solubility and instability of the ITI-007 free base.

Thymosin beta4 stimulates oligodendrocyte progenitor cell migration and differentiation to restore axonal myelination after stroke or multiple sclerosis injury.

Valproic acid adjuvant improves dopaminergic neuron retention by accelerating differentiation, resolving low survival rates in Parkinson's cell therapy.

High-temperature heating of solar salt creates a functional composition that reduces dementia frequency by blocking pathological initiators.

A CRISPR/Cas9 system targets the dystrophin gene to enable stable genome modification in muscle tissue.

Serological assays measure PACAP and SIRT3 concentrations to diagnose Alzheimer's disease and administer treatments that restore neurotrophic activity.

Replacing toxic solvents with biocompatible oligomeric liquids eliminates patient irritation while maintaining polymer solubility for controlled drug release.

Monoclonal antibodies target mutant SOD1 proteins to delay disease onset and reduce motor neuron loss, addressing the lack of effective therapies for ALS.

IL-25 binding monoclonal antibodies neutralize cytokine activity to address ineffective clinical remission in inflammatory bowel disease and asthma.

Inhibiting osteopontin expression reduces amyloid beta-induced neuronal cell death and modulates inflammatory protein levels.

Polymerized peptides lacking human protein homology reduce amyloid burden and cognitive decline without cell-mediated toxicity.

Allosteric modulators bind the M1 receptor to enhance cognition while reducing gastrointestinal side effects from off-target activation.

Point mutations in domains 2 and 3 increase melting temperature, extending functional half-life to resolve protein instability.

FACS separates neural progenitors by marker expression to eliminate cellular heterogeneity and reduce tumor formation risk.

Ethanol and citrate buffer stabilize the atropine-scopolamine formulation for 24 months, reducing toxicity from high doses.

Measuring IL-21 levels and genotyping SNPs identifies multiple sclerosis patients at risk for secondary autoimmunity following lymphocyte depletion.

Small peptide chemokine antagonists block specific receptors to induce synapse regeneration, reversing cognitive deficits caused by neuronal degradation.

Small molecule C1 crosses the blood-brain barrier to activate TFEB without MTOR inhibition, reducing toxic protein aggregates.

Polysubstituted hexaric acids reduce beta-amyloid toxicity and promote neuronal survival in Alzheimer's disease.

Oral cannabinoid compositions increase MAP kinase phosphatase expression in neurons and glial cells to modulate cellular signaling cascades.

Polylactide microspheres deliver donepezil via hydrolysis, resolving low drug content and non-uniform particle size issues.

Alpha-asaronol esters combine TMCA and asarone pharmacophores to deliver brain protection.

Acetylated CD44vRA peptides inhibit joint inflammation by competing with natural ligands, avoiding non-specific immune suppression.

A selective muscarinic M1 and M4 receptor agonist treats neurodegenerative disorders.

FSTL-1 antagonists block proinflammatory cytokine expression and Th17 cell induction, addressing inadequate modulation of inflammatory conditions.

Segmented prodrug molecules bypass membrane barriers and enzymatic deficits to restore mtDNA levels in depletion syndrome patients.

TG02 ERK5 inhibitor prolongs survival in pediatric patients with H3K27M-mutant tumors by blocking aberrant signaling pathways.

Periodic glatiramer acetate dosing reduces injection-site reactions and relapses while maintaining disease control.

CRISPR/Cas editing reduces TTR protein levels, addressing the need for long-lasting suppression of disease progression.

A solid dispersion transdermal system uses polymeric stabilizers to maintain therapeutic agents in an amorphous form for enhanced skin absorption.

Chemical entities inhibit excessive STING signaling to treat autoinflammatory disorders while preserving antiviral immunity.

Antibody-based FAM19A5 detection replaces subjective clinical assessments to resolve diagnostic accuracy trade-offs in mood disorder evaluation.

Adiponectin receptor-activating novel peptides reduce APP and amyloid beta protein expression while avoiding cytotoxicity to treat Alzheimer's disease.

A TNFR2-IL21R fusion protein acts as a double antagonist to reduce inflammatory cytokine secretion and increase anti-inflammatory cytokine production.

Heterologous enzyme expression in transgenic microalgae resolves rate-limiting biosynthetic steps, boosting omega-3 yields for sustainable aquaculture.

Tissue-specific promoters localize miRNA expression to reduce androgen receptor levels while preventing off-site effects.

A pet food composition incorporating specific metabolites to modulate phosphorus, alkaline phosphatase, and gamma-glutamyltransferase levels in companion animals.

Conjugating a CNS homing peptide with nonsteroidal anti-inflammatory drugs targets delivery across the blood-brain barrier, reducing systemic side effects.

Bridged cyclic compounds selectively modulate PI3Kγ kinase activity, addressing the trade-off between disease suppression efficacy and toxicity.

Segmented pellets within a layered carrier prevent diffusion of osteogenic substances, ensuring precise retention at the fusion site.

Merges 5-HT4 agonists with low-dose acetylcholinesterase inhibitors to increase sAPPα levels while minimizing side effects.